研究组长介绍

徐颖洁, 博士，课题组长，博士生导师。本科及硕士毕业于上海第二医科大学临床医学七年制英文班，2011年在加拿大麦吉尔大学实验医学系获得博士学位，2011-2017年于美国哈佛医学院波士顿儿童医院从事博士后研究。2017年7月加入上海交通大学医学院生物化学和细胞分子生物学系担任课题组长。

研究方向与进展

1.介导癌症转移及耐药的分子靶点发现,机制探究和靶向治疗评估

2.优化mRNA的体外合成与体内递送

3. 研发基于mRNA的治疗应用:包括癌症mRNA疫苗,感染性疾病mRNA疫苗, mRNA的蛋白替代疗法在癌症及其他疾病中的应用

科研项目

1、国家自然科学基金面上项目，81872345，PTEN的蛋白磷酸酶功能调控Foxk1的活性在前列腺癌发生中的作用与机制，2019.01-2022.12，在研，项目负责人

2、上海市科技计划项目，18PJ1406700，Prohibitin复合体介导的肺癌耐药作用机制和靶向，2018.07-2020.06，结题，项目负责人

3、上海交通大学医学院-希伯来大学种子基金项目，抑制新冠病毒入侵的药物筛选研究，2020.07-2023.06，在研，项目负责人

代表性论文、专著与专利

· Zhang J, Yin Y, Wang J, Zhang J, Liu H, Feng W, Yang W, Zetter B, Xu Y*.  Prohibitin regulates mTOR pathway via the interaction with FKBP8. Frontiers of Medicine. 2020 (In press)

· Lu J, Lu G, Tan S, Xia J, Xiong H, Yu X, Qi Q, Yu X, Li L, Yu H, Xia N, Zhang T, Xu Y*, Lin J. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Research. 2020, 30（936-939）. (*Co-corresponding author)

· Saw PE, Zhang A, Nie Y, Zhang L, Xu Y*, Xu X. Tumor-associated fibronectin targeted liposomal nanoplatform for cyclophilin A siRNA delivery and targeted malignant glioblastoma therapy. Frontier in Pharmacology. 2018 (*Co-corresponding author)

· Islam MA, Xu Y*, Tao,W, Ubellacker  JM, Lim M, Aum D, Lee GY, Zhou K, Zope HR,Yu M, Cao W, Oswald JT, Dinavand M, Mahmoudi M, Langer R, Kantoff PK, Farokhzad OC, Zetter BR, Shi J.  Restoration of tumor suppression in vivo by systemic delivery of chemically modified PTEN mRNA nanoparticles.  Nat. Biomed. Eng.2018 Sep 18 online.  (*Co-first author)

· Yang W, Nagasawa K, Münch C, Xu Y, Satterstrom K, Jeong S, Hayes SD, Jedrychowski MP, Vyas FS; Zaganjor E, Guarani V, Ringle A, Gygi SP, Harper JW, Haigis MC.  Mitochondrial Sirtuin Network Reveals Dynamic SIRT3-dependent Deacetylation in Response to Membrane Depolarization. Cell. 2016 Nov; 4(167):985-1000

· Xu Y, Yang W, Shi J, Zetter BR. Prohibitin 1 regulates tumor cell apoptosis via interaction with X-linked Inhibitor of Apoptosis Protein. J Mol Cell Biol. 2016 Jun; 8(3):282-5. doi: 10.1093/jmcb/mjw018.

· Islam MA, Reesor EK, Xu Y, Zope HR, Zetter BR, Shi J. Biomaterial for mRNA delivery. Biomater Sci. 2015 Dec 10;3(12):1519-33. doi: 0.1039/c5bm00198f. Epub 2015 Aug 17.

· Zhu X, Xu Y*, Solis LM, Tao W, Wang L, Behrens C, Xu X, Zhao L, Liu D, Wu J, Zhang N, Wistuba II, Farokhzad OC, Zetter BR, Shi J. Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7779-84. (*Co-first author)

· Shi J, Xu Y*, Xu X, Zhu X, Pridgen E, Wu J, Alexander V, Zetter BR, Farokhzad O. Hybrid Lipid-Polymer Nanoparticles for Sustained siRNA Delivery and Gene Silencing. Nanomedicine. 2014 Mar 17. pii: S1549-9634(14)00124-5. doi: 10.1016/j.nano.2014.03.006. (*Co-first author)

· Xu Y, Bismar TA, Su J, Xu B, Kristiansen G, Varga Z, Teng L, Ingber DE, Mammoto A, Kumar R, Alaoui-Jamali MA. Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J Exp Med. 2010 Oct 25;207(11):2421-37. Epub 2010 Oct 11.

· Alaoui-Jamali MA, Bismar TA, Gupta A, Szarek WA, Su J, Song W, Xu Y, Xu B, Liu G, Vlahakis JZ, Roman G, Jiao J, Schipper HM. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer. Cancer Res. 2009 Oct 15;69(20):8017-24. Epub 2009 Oct 6.

· Bijian K, Mlynarek AM, Balys RL, Jie S, Xu Y, Hier MP, Black MJ, Di Falco MR, LaBoissiere S, Alaoui-Jamali MA. Serum proteomic approach for the identification of serum biomarkers contributed by oral squamous cell carcinoma and host tissue microenvironment. J Proteome Res. 2009 May;8(5):2173-85.

· Xu Y, Benlimame N, Su J, He Q, Alaoui-Jamali MA. Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells. Br J Cancer. 2009 Feb 24;100(4):633-43. Epub 2009 Feb 3.

· Behmoaram E, Bijian K, Jie S, Xu Y, Darnel A, Bismar TA, Alaoui-Jamali MA. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness. Am J Pathol. 2008 Nov;173(5):1540-50. Epub 2008 Oct 2.

· Benlimame N, He Q, Jie S, Xiao D, Xu Y, Loignon M, Schlaepfer DD, Alaoui-Jamali MA. FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Biol. 2005 Nov 7;171(3):505-16.

团队介绍

于翔,博士, 助理研究员,邮箱:yuxiang@shsmu.edu.cn

殷亚男,硕士,技术员,邮箱: yinyanan@shsmu.edu.cn

黄玛莎，博士，博士后，邮箱：martha0126@163.com

张佳慧，博士研究生，邮箱：jiahui_zhang@sjtu.edu.cn

张宇，硕士研究生，邮箱：sjtuzhangyu@sjtu.edu.cn

张静静，博士研究生（联合培养），邮箱：1334145742@qq.com